Cytomel (Liothyronine) Cost in Delaware 2026

What Does Cytomel (Liothyronine) Actually Cost in Delaware in 2026?

The cash-pay cost of generic liothyronine at Delaware retail pharmacies averages around $35 per month in 2026 when a discount card is applied. Branded Cytomel carries a Pfizer wholesale acquisition cost near $120 per month, but almost no patient should pay that figure without checking alternatives first. The gap between those two numbers is where smart pharmacy shopping lives.

Liothyronine is the synthetic form of triiodothyronine (T3), the active thyroid hormone. The FDA approved Cytomel (liothyronine sodium) for hypothyroidism, pituitary TSH suppression, and thyroid suppression testing [1]. Generic versions from multiple manufacturers have been on the US market for years, which explains the large price spread between list and street price.

Pricing at specific Delaware pharmacies varies by chain contracts and dispensing fees. A 30-day supply of liothyronine 25 mcg tablets runs approximately $18 to $45 at Walgreens, CVS, and Rite Aid locations in Wilmington, Dover, and Newark when a GoodRx or SingleCare coupon is presented. Without a coupon, the same supply at the same chains may run $60 to $90. Price transparency tools maintained by the FDA encourage patients to compare costs across dispensers [2].

Dose affects total monthly cost. Patients on 5 mcg once daily spend less than patients on 25 mcg twice daily. A clinician titrating from 25 mcg to 50 mcg per day roughly doubles the tablet burden and, absent a coupon, doubles out-of-pocket spend. Bunevicius et al. (NEJM, 1999) showed that a combination T4/T3 regimen with liothyronine at 12.5 mcg daily produced measurable improvements in mood and neuropsychological function versus levothyroxine alone in 33 patients [3], suggesting clinical situations exist where T3 supplementation is appropriate and dose matters.

Research published in JAMA confirms that thyroid hormone therapy decisions should account for both efficacy and cost burden to promote adherence [4]. Low out-of-pocket cost is directly associated with better medication adherence in chronic conditions managed with daily oral tablets.

Delaware Medicaid Coverage for Liothyronine

Delaware Medicaid (Diamond State Health Plan) covers liothyronine with a prior authorization (PA) requirement. PA is not automatic. Prescribers must document that the patient has a qualifying diagnosis, typically hypothyroidism or thyroid cancer requiring TSH suppression, and that the clinical rationale supports T3 therapy rather than levothyroxine monotherapy alone.

The Delaware Division of Medicaid and Medical Assistance publishes its preferred drug list through the Delaware Health and Social Services portal [5]. Liothyronine sits in a non-preferred tier for most managed care plans operating under the Diamond State Health Plan umbrella, which is why PA applies. Levothyroxine is preferred. A prescriber who documents residual hypothyroid symptoms despite optimized levothyroxine therapy, or who cites a patient's inability to convert T4 to T3 (deiodinase polymorphism), generally meets the PA threshold.

Once PA is approved, Medicaid enrollees pay a minimal or zero copay. The PA approval period is typically 12 months, after which re-authorization is required. Patients should ask their prescriber to initiate the PA at the time of the initial prescription to avoid a coverage gap.

The American Association of Clinical Endocrinology (AACE) guidelines state: "Combination therapy with levothyroxine plus liothyronine may be considered for patients who do not feel well on levothyroxine alone, after excluding other causes" [6]. That language gives prescribers a documented clinical basis for PA submissions.

Is Compounded Liothyronine T3 Legal in Delaware?

Yes. Compounded liothyronine T3 is legal in Delaware when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. 503A pharmacies compound for individual patients based on a practitioner's prescription under Section 503A of the Federal Food, Drug, and Cosmetic Act [7].

503A pharmacies differ from 503B outsourcing facilities. A 503B facility may compound without a patient-specific prescription and distribute across state lines in bulk. Most compounding pharmacies filling individual T3 prescriptions for Delaware patients are 503A. Both models are subject to FDA oversight and state Board of Pharmacy regulation [7].

Compounded liothyronine runs approximately $40 per month in Delaware. That is modestly higher than the $35 average for a generic tablet but may offer advantages in specific clinical situations: patients needing non-standard doses, patients with documented tablet excipient sensitivities, or patients prescribed a sustained-release T3 formulation (though evidence for superior outcomes with sustained-release compounded T3 remains limited) [8].

Prescribers should be aware that compounded T3 formulations are not FDA-approved and lack the bioequivalence data required of approved generics. The FDA has noted quality control concerns with some compounded thyroid preparations [9]. A board-certified endocrinologist or prescribing clinician should weigh that trade-off explicitly before defaulting to a compound over a generic tablet.

Delaware's Board of Pharmacy regulates 503A pharmacies under Title 24 of the Delaware Code. Patients can verify a compounding pharmacy's licensure through the Delaware Division of Professional Regulation before filling [10].

How Delaware Insurance Plans Handle Cytomel and Liothyronine Coverage

Commercial insurance plans available through the Delaware marketplace, including those offered by Highmark Blue Cross Blue Shield of Delaware and Aetna, generally place generic liothyronine on Tier 1 or Tier 2 of their formularies, resulting in copays of $10 to $25 per 30-day supply. Branded Cytomel typically lands on Tier 3 or Tier 4, where cost-sharing may reach $50 to $80 per fill without manufacturer assistance.

Employer-sponsored plans in Delaware follow a similar pattern. The majority of pharmacy benefit managers, including Express Scripts and CVS Caremark, treat liothyronine generics as preferred and branded Cytomel as non-preferred. Patients requesting the brand-name product when a generic is available may face a dispense-as-written (DAW) penalty on top of the standard cost-sharing.

Step therapy requirements exist in some plans. A plan may require documented failure or contraindication to levothyroxine monotherapy before authorizing liothyronine coverage at any tier. Prescribers can appeal step therapy decisions under Delaware's step therapy law (Delaware Code Title 18, Chapter 33), which requires insurers to grant exceptions when step therapy is clinically inappropriate [11].

Medicare Part D plans covering Delaware beneficiaries also vary. Most Part D formularies include generic liothyronine, but coverage at low cost-sharing often requires the use of preferred network pharmacies. Beneficiaries should compare plans each October during open enrollment using the CMS Plan Finder tool.

The Cheapest Way to Get Liothyronine in Delaware

Generic liothyronine with a GoodRx or SingleCare coupon at a high-volume retail pharmacy is typically the lowest-cost option for uninsured or underinsured Delaware patients. Prices shift frequently. Checking multiple discount platforms on the day of filling sometimes reveals a $5 to $10 difference on the same 30-day supply.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) listed liothyronine 25 mcg tablets at under $10 for a 90-day supply as of early 2026. That pricing model, which applies a fixed 15% markup over manufacturing cost plus a $3 dispensing fee and $5 shipping, consistently undercuts traditional retail chains for generic thyroid medications [12]. Delaware residents can order online and receive the medication by mail.

Pfizer's patient assistance program (Pfizer RxPathways) may cover branded Cytomel at no cost for patients below 400% of the federal poverty level who lack adequate insurance coverage. The program application is available at pfizeroncology.com and requires income documentation. Eligibility reviews typically complete within 5 to 10 business days.

The HealthRX Cost Decision Framework for liothyronine in Delaware runs as follows. First, confirm whether your insurance formulary covers generic liothyronine at Tier 1 or Tier 2. Second, if uninsured or if your copay exceeds $20, compare GoodRx, SingleCare, and Cost Plus Drugs pricing on the day you fill. Third, if your prescriber has recommended compounded T3, verify the pharmacy's Delaware 503A license and ask for a Certificate of Analysis for each batch. Fourth, if you require branded Cytomel specifically, check Pfizer RxPathways before paying list price.

Telehealth Access to Liothyronine Prescriptions in Delaware

Telehealth prescribing of Cytomel and generic liothyronine is legal in Delaware. The Delaware Telehealth Act permits licensed physicians, advanced practice registered nurses (APRNs), and physician assistants (PAs) to conduct synchronous audio-video evaluations and issue prescriptions for non-controlled substances, including liothyronine, without a prior in-person visit [13].

Liothyronine is not a controlled substance under the DEA schedule. That classification matters because it means no Ryan Haight Act restriction applies. A telehealth clinician can prescribe liothyronine after a qualifying audio-video encounter and appropriate laboratory review, specifically TSH, free T4, and free T3 levels.

HealthRX clinicians licensed in Delaware follow a protocol requiring baseline thyroid panel results dated within 90 days before initiating liothyronine. Starting doses typically range from 5 mcg to 25 mcg once daily, with uptitration based on repeat labs at 6-week intervals. The American Thyroid Association recommends that TSH remain within the normal reference range during T3 supplementation to minimize cardiovascular risk [14].

Patients with atrial fibrillation, coronary artery disease, or osteoporosis require more conservative dosing. Exogenous T3 can raise resting heart rate and increase myocardial oxygen demand. A prospective cohort study published in JAMA Internal Medicine (N=201,085) found that suppressed TSH was associated with a 2.3-fold increase in atrial fibrillation risk [15], which is a relevant consideration when T3 is added to an existing levothyroxine regimen.

A telehealth visit typically costs $50 to $150 for new patients in Delaware if paying out of pocket. Many Delaware commercial insurers reimburse telehealth at parity with in-person visits under state parity law, effective since 2017 [13].

How Cytomel and Liothyronine Are Used Clinically

Liothyronine is a T3 receptor agonist with a half-life of roughly 1 day, far shorter than levothyroxine's 7-day half-life [1]. That pharmacokinetic difference drives the twice-daily dosing common in clinical practice. The shorter half-life also means that missing a dose produces a faster drop in circulating T3 and a faster return to euthyroid state after discontinuation, which is clinically useful in thyroid cancer surveillance protocols requiring thyroid hormone withdrawal.

Approved indications include hypothyroidism as monotherapy or adjunct, myxedema coma (intravenous formulation), pituitary TSH suppression in thyroid cancer, and the T3 suppression test for diagnosing hyperthyroidism [1]. Off-label use includes adjunctive therapy in treatment-resistant depression; a meta-analysis published in Acta Psychiatrica Scandinavica (N=292 patients across 4 RCTs) found a response rate 23% higher with T3 augmentation of tricyclic antidepressants versus placebo [16].

Bunevicius et al. (NEJM, 1999) conducted a randomized crossover trial in 33 patients with hypothyroidism, replacing 50 mcg of levothyroxine with 12.5 mcg of liothyronine. The T3/T4 combination produced better scores on 17 of 19 neuropsychological and mood measures compared to levothyroxine alone (P<0.05) [3]. That study is frequently cited by clinicians who advocate for combination therapy, though larger replication trials have produced mixed results [17].

Standard FDA-approved dosing for adult hypothyroidism starts at 25 mcg once daily. Geriatric patients or those with cardiovascular disease start at 5 mcg daily. The ceiling dose in clinical practice is typically 75 mcg per day, though higher doses appear in thyroid cancer suppression protocols under specialist supervision [1].

Monitoring Requirements and Safety Considerations

Initiating liothyronine requires baseline thyroid function tests and a cardiovascular history. TSH should be checked 6 weeks after any dose change because T3's short half-life means the hypothalamic-pituitary axis re-equilibrates faster than with levothyroxine adjustments. Free T3 levels are not universally required but help confirm absorption and guide titration in patients with GI absorption concerns [14].

Bone mineral density monitoring applies to patients on chronic liothyronine, particularly postmenopausal women. A systematic review in Endocrine Reviews (N=41 studies) found that exogenous thyroid hormone exceeding replacement levels was associated with significantly lower lumbar spine BMD (effect size: -0.23 SD) [18]. Dual-energy X-ray absorptiometry (DEXA) scanning at baseline and every 2 years is appropriate for long-term users.

Drug interactions are clinically meaningful. Calcium carbonate, ferrous sulfate, and proton pump inhibitors reduce T3 absorption when taken within 4 hours. Warfarin dose requirements may decrease with thyroid hormone initiation because T3 accelerates vitamin K-dependent clotting factor catabolism [1]. Prescribers should flag these interactions at the time of prescribing.

Symptoms of over-replacement include palpitations, tremor, heat intolerance, and unintended weight loss. Under-replacement manifests as fatigue, constipation, cold intolerance, and weight gain. Regular follow-up at 6-week intervals after initiation and annually once stable is standard of care per ATA guidelines [14].

Delaware-Specific Pharmacy Resources

Delaware has four counties and approximately 1 million residents. Retail pharmacy density is highest in New Castle County, where Wilmington-area chains offer competitive pricing. Kent and Sussex counties have fewer retail options, making mail-order and telehealth pharmacy services especially relevant for patients in those areas.

The Delaware Prescription Assistance Program (DPAP) provides co-payment assistance for qualifying low-income residents on certain medications. Liothyronine eligibility under DPAP depends on annual income thresholds and current program funding cycles. Patients can apply through the Delaware Division of Services for Aging and Adults with Physical Disabilities. Income limits for 2026 are indexed to 200% of the federal poverty level [19].

The Delaware Health Care Commission publishes aggregate pharmacy pricing data annually. Generic liothyronine consistently appears among the top-50 most-dispensed thyroid medications in the state, reflecting a substantial patient population that benefits from price transparency [20].